NMN raises NAD+ in people (MIB-626); FDA excluded it (2022) then reversed (2025)
NAD+ decline with age is mainstream biology. Sinclair co-founded Metro International Biotech (MIB), whose crystalline NMN drug MIB-626 raised circulating NAD+ in a human PK trial (Pencina et al., J Gerontol A, 2022). Because MIB-626 was under an IND, the FDA ruled in Nov 2022 that NMN was excluded from the dietary-supplement definition; it paused enforcement in Oct 2024 and reversed course in Sept 2025, declaring NMN lawful in supplements again. Not established: that NMN extends human healthspan or lifespan.
NAD+ (nicotinamide adenine dinucleotide), a coenzyme central to cellular energy metabolism, declines with age — this part is uncontroversial mainstream biology. Sinclair co-founded Metro International Biotech (MIB), which developed a crystalline form of NMN (nicotinamide mononucleotide), MIB-626, as an NAD+-boosting drug candidate. A human pharmacokinetic trial confirmed MIB-626 does raise circulating NAD+ levels in people. Separately, because MIB-626 was under an active FDA Investigational New Drug (IND) application, the FDA ruled in November 2022 that this made NMN a drug ingredient — legally excluding it from the dietary-supplement definition under the Food, Drug, and Cosmetic Act. The agency paused enforcement of that exclusion in October 2024 and then reversed its position entirely in September 2025, declaring NMN lawful for sale in dietary supplements again.
Why it matters (spine): this card is a template for the kind of claim HKG exists to untangle — three distinct, separately-evidenced statements ("NAD+ declines with age," "NMN raises NAD+ in humans," "NMN produces anti-aging benefit in humans") get collapsed into one marketing sentence in the wild. It is also a live regulatory-whiplash case, exactly the kind of fast-decaying fact this garden's freshness dating exists to track.
Live status / Provenance: Pencina et al., Journals of Gerontology: Series A (2022), human PK data on MIB-626 (Metro International Biotech, co-founded by David A. Sinclair; credited). FDA regulatory history: exclusion ruling Nov 2022, enforcement pause Oct 2024, reversal declaring NMN lawful in supplements Sept 2025 (source: nmn.com regulatory summary, 30 Sept 2025, citing FDA action). As of this card, NMN is legally sold as a supplement, but no human RCT has established a healthspan or lifespan benefit.
So we should keep the three claims separated on the record every time this topic comes up, flag the conflict of interest plainly — Sinclair promoted NMN as a consumer supplement while co-founding a company pursuing FDA drug approval for essentially the same molecule — and treat the regulatory status as provisional pending the next FDA action.
Separate three things cleanly for HKG: NAD+ biology (solid), NMN raising NAD+ (shown), NMN "anti-aging" in humans (unproven). Flag the conflict of interest — Sinclair promoted NMN as a supplement while co-founding the company seeking to sell it as a drug.
domains: longevity · biomarkers · aging · regulatory · supplements